课题基金 / 基金详情

Targeting colorectal cancer-initiating cells and anti-EGFR therapeutic resistance by manipulating levels of the reactive aldehyde, 4-hydroxynonenal

Targeting colorectal cancer-initiating cells and anti-EGFR therapeutic resistance by manipulating levels of the reactive aldehyde, 4-hydroxynonenal
通过控制活性醛 4-羟基壬烯醛的水平,靶向结直肠癌起始细胞和抗 EGFR 治疗耐药性
批准号:
281581
负责人:
O'Brien Catherine A
金额:
$45.58万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-03-01 至 2017-03-01

项目摘要

项目成果

O'Brien Catherine A的其他基金

相似基金

相关文献

中文摘要
翻译
结直肠癌(CRC)是加拿大癌症死亡的第二大原因,每年有9,200人死亡。我们先前已经表明,CRC是由结肠直肠癌起始细胞(CC-IC)的子集启动和维持的。此外,
英文摘要
Colorectal cancer (CRC) is the 2nd leading cause of cancer mortality in Canada, with 9,200 deaths annually. We have previously shown that CRCs are initiated and maintained by a subset of colorectal cancer-initiating cells (CC-ICs). There is also increasin
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Inhibition of CBP/p300 bromodomain activity increases chemosensitivity of p53 mutant colorectal cancers through inhibiting p53 aggregation
  • 批准号:
    472399
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    O'Brien Catherine A
  • 依托单位:
Molecular drivers of the drug tolerant persister state in patient-derived colorectal cancer models
  • 批准号:
    434963
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.94万
  • 财政年份:
    2020
  • 负责人:
    O'Brien Catherine A
  • 依托单位:
Canada Research Chair - Tier 2
  • 批准号:
    415401
  • 项目类别:
  • 资助金额:
    $43.71万
  • 财政年份:
    2019
  • 负责人:
    O'Brien Catherine A
  • 依托单位:
Colorectal cancer stem cell plasticity: A novel therapeutic target
  • 批准号:
    334266
  • 项目类别:
    Operating Grants
  • 资助金额:
    $88.93万
  • 财政年份:
    2015
  • 负责人:
    O'Brien Catherine A
  • 依托单位:
海外基金